<DOC>
	<DOCNO>NCT00014443</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide may stop growth cancer stop blood flow tumor . PURPOSE : Phase I trial study effectiveness combine topotecan thalidomide treat patient recurrent refractory malignant glioma .</brief_summary>
	<brief_title>Topotecan Thalidomide Treating Patients With Recurrent Refractory Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine tumor response rate , duration response , time disease progression , overall survival patient recurrent refractory malignant glioma treat topotecan thalidomide . - Determine safety tolerance regimen patient . OUTLINE : Patients receive topotecan IV continuously day 1-21 oral thalidomide daily day 1-28 . Treatment repeat every 28 day maximum 6 course absence disease progression unacceptable toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : Approximately 20 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent progressive supratentorial glioblastoma anaplastic astrocytoma Measurable disease MRI CT scan No gliomatosis cerebri , anaplastic oligodendroglioma , anaplastic oligoastrocytoma Concurrent registration System Thalidomide Education Prescribing Safety ( S.T.E.P.S . ) program PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 1.6 mg/dL Other : No concurrent malignancy except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception 1 month prior , , 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 2 prior chemotherapy regimen adjuvant metastatic setting At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Concurrent anticonvulsant allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>